Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients (Prevention of Relapses and Delay of Progression of Physical Disability in Secondary Progressive Multiple Sclerosis)
Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients (Prevention of Relapses and Delay of Progression of Physical Disability in Secondary Progressive Multiple Sclerosis)
This study is a single cohort, central registration system, all-case, open-label, multicenter observational study in patients using Mayzent for the indication of secondary progressive multiple sclerosis.
This is a non-interventional study, and as such there is no binding treatment strategy, diagnosis/treatment procedures or visit schedule. The investigator should administer Mayzent as labelled. Routine medical practice will apply to visit frequency and evaluation variables, and only these data will be collected by the sponsor as part of the study procedures. The investigator should record data in the applicable CRFs at every visit if possible.
Inclusion Criteria:
Exclusion Criteria:
-
Kita-gun, Kagawa-ken 761-0793, Japan
Ashigarakami, Kanagawa 258-0003, Japan
Chiisagata, Nagano 386-0603, Japan
Kitaazumi, Nagano 399-8601, Japan
Iruma-gun, Saitama 350-0495, Japan
Ohtsu-city, Shiga 520-2192, Japan
Adachi-ku, Tokyo 121-0061, Japan
Bunkyo Ku, Tokyo 113 8655, Japan
Bunkyo Ku, Tokyo 113-8431, Japan
Bunkyo-ku, Tokyo 113-8519, Japan
Itabashi Ku, Tokyo 173 8606, Japan
Shinagawa-ku, Tokyo 142-8666, Japan
Shinjuku Ku, Tokyo 162 8666, Japan
Shinjuku-ku, Tokyo 160 8582, Japan
Shinjuku-ku, Tokyo 160-0023, Japan